APOE and Alzheimer disease: For example, Murray et al. have reported that, when AD autopsy cases were divided into three distinct groups based on the regional pattern of the NFT pathology observed (“hippocampal-sparing,” “typical,” and “limbic predominant”), there was a trend towards fewer APOE4 carriers in the “hippocampal-sparing” AD group, and there were significantly more late-onset (greater than 65 years old at diagnosis) APOE4 carriers vs. non-carriers in the “limbic predominant” AD group [61].